{"id":124960,"date":"2020-09-06T17:14:48","date_gmt":"2020-09-06T21:14:48","guid":{"rendered":"https:\/\/ipwatchdog.com\/?post_type=tribe_events&p=124960"},"modified":"2022-09-30T12:31:30","modified_gmt":"2022-09-30T16:31:30","slug":"coronavirus-vaccine","status":"publish","type":"tribe_events","link":"https:\/\/ipwatchdog.com\/event\/coronavirus-vaccine\/","title":{"rendered":"IPW Webinar – The Race for a Coronavirus Vaccine: The Intersection of Science & IP Policy"},"content":{"rendered":"
<\/a><\/p>\n The term \u201ccoronavirus\u201d and the disease COVID-19 have become ubiquitous in daily communications across the globe. While many initially asked why testing for the coronavirus that causes COVID-19 was slow to roll out, and why tests in many countries were inaccurate, one question no one seems to be asking is why the pursuit of a vaccine is going so slow. Indeed, by all reports from both public and private sectors, the first viable vaccines are months, if not weeks away.<\/p>\n \u201cAll of what is being accomplished today is the result of years of innovation,\u201d said USPTO Director Andrei Iancu in a recent interview with IPWatchdog.com. \u201cIt is important not to lose track of that.\u201d Indeed, the fact that multiple companies are racing toward a vaccine in unprecedented time frames is precise because of the vast amounts of research and development that have taken place in the years leading up to the current COVID-19 pandemic.<\/p>\n Amidst this backdrop, join Gene Quinn<\/strong><\/a><\/span>, patent attorney and leading commentator on patent law and innovation policy, Gene will host a wide-ranging conversation on the topic of COVID-19 and the race toward a coronavirus vaccine. In addition to discussing the science and FDA processes involved, we discuss intellectual property rights and more. Joining Gene will be immunization expert Dr. Jonathan Temte<\/strong><\/a><\/span>, a Professor at the Wisconsin School of Medicine who also serves as a member of the CDC\u2019s Board of Scientific Counselors, and Melissa Bran<\/span>d<\/strong><\/a><\/span>, Assistant General Counsel for Intellectual Property at the Biotechnology Innovation Organization, and\u00a0Erika Lietzan<\/span><\/a>,\u00a0\u00a0<\/strong>Associate Professor of Law at the University of Missouri School of Law.<\/p>\n This webinar is sponsored by Morningside IP<\/a><\/strong><\/span>.<\/p>\n